This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children and adolescents with generalized anxiety disorder (GAD), separation anxiety disorder (SAD), or social phobia/social anxiety disorder.
Methods:
Youth aged 6–17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1–6 mg daily, n = 62) or placebo (n = 21) for 12 weeks. The primary aim of this study was to determine the safety and tolerability of GXR in youth with anxiety disorders, which involved the analysis of treatment-emergent adverse events (TEAEs), the emergence of suicidal ideation and behaviors, vital signs, and electrocardiographic/laboratory parameters. Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression–Improvement (CGI-I) scale. As this was an exploratory study, no inferential statistical analyses were performed.
Results:
GXR was safe and well tolerated. Treatment-related mean ± standard deviation changes in heart rate (GXR: 1.8 ± 12 beats per minute [bpm] decrease; placebo: 0.5 ± 11 bpm decrease), systolic blood pressure (GXR: 2.3 ± 11 mm Hg decrease; placebo: 1.7 ± 11 mm Hg decrease), or diastolic blood pressure (GXR: 1.3 ± 9 mm Hg decrease; placebo: 0.9 ± 7 mm Hg increase) were similar between treatment groups. TEAEs, including headache, somnolence/fatigue, abdominal pain, and dizziness, were consistent with the known safety profile of GXR. No differences were observed between treatment groups for PARS and SCARED scores, although at endpoint, a higher proportion of subjects receiving GXR versus placebo demonstrated CGI-I scores ≤2 (54.2% vs. 31.6%), as rated by the clinician investigator.
Conclusions:
GXR was well tolerated in pediatric subjects with GAD, SAD, and/or social anxiety disorder.
ClinicalTrials.govIdentifier:
NCT01470469.
Get full access to this article
View all access options for this article.
References
1.
Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Edited by RockvilleGuy W.MD, U.S. Department of Health, Education, and Welfare, 1976, pp 218–222.
2.
The Research Units on Pediatric Psychopharmacology Anxiety Study Group: The Pediatric Anxiety Rating Scale (PARS): Development and psychometric properties. J Am Acad Child Adolesc Psychiatry, 41:1061–1069, 2002.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC, American Psychiatric Association, 2000.
4.
ArnstenAF, JinLE: Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. Yale J Biol Med, 85:45–58, 2012.
5.
ArnstenAF, ScahillL, FindlingRL: Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from new data. J Child Adolesc Psychopharmacol, 17:393–406, 2007.
6.
BeesdoK, KnappeS, PineDS: Anxiety and anxiety disorders in children and adolescents: Developmental issues and implications for DSM-V. Psychiatr Clin North Am, 32:483–524, 2009.
7.
BeesdoK, PineDS, LiebR, WittchenHU: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry, 67:47–57, 2010.
8.
BiedermanJ, MelmedRD, PatelA, McBurnettK, KonowJ, LyneA, SchererN: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121:e73–e84, 2008.
9.
BirmaherB, KhetarpalS, BrentD, CullyM, BalachL, KaufmanJ, NeerSM: The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry, 36:545–553, 1997.
10.
BirnbaumSG, PodellDM, ArnstenAF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav, 67:397–403, 2000.
11.
BlackfordJU, PineDS: Neural substrates of childhood anxiety disorders: A review of neuroimaging findings. Child Adolesc Psychiatr Clin N Am, 21:501–525, 2012.
12.
BlochMH, PanzaKE, Landeros-WeisenbergerA, LeckmanJF: Meta-analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adoles Psychiatry, 48:884–893, 2009.
13.
BremnerJD, KrystalJH, SouthwickSM, CharneyDS: Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse, 23:28–38, 1996.
14.
BuchelerMM, HadamekK, HeinL: Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience, 109:819–826, 2002.
15.
ChaviraDA, SteinMB, BaileyK, SteinMT: Child anxiety in primary care: Prevalent but untreated. Depress Anxiety, 20:155–164, 2004.
16.
CoffeyB, BiedermanJ, SmollerJW, GellerD, SarinP, SchwartzS, KimG: Anxiety disorders and tic severity in juveniles with Tourette's disorder. J Am Acad Child Adoles Psychiatry, 39:562–568, 2000.
17.
ComptonSN, PerisTS, AlmirallD, BirmaherB, SherrillJ, KendallPC, MarchJS, GoschEA, GinsburgGS, RynnMA, PiacentiniJC, McCrackenJT, KeetonCP, SuvegCM, AschenbrandSG, SakolskyD, IyengarS, WalkupJT, AlbanoAM: Predictors and moderators of treatment response in childhood anxiety disorders: Results from the CAMS trial. J Consult Clin Psychol, 82:212–224, 2014.
18.
ComptonSN, WalkupJT, AlbanoAM, PiacentiniJC, BirmaherB, SherrillJT, GinsburgGS, RynnMA, McCrackenJT, WaslickBD, IyengarS, KendallPC, MarchJS: Child/adolescent Anxiety Multimodal Study (CAMS): Rationale, design, and methods. Child Adolesc Psychiatry Ment Health, 4:1, 2010.
19.
ConnollySD, BernsteinGA: Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry, 46:267–283, 2007.
20.
ConnorDF, FindlingRL, KollinsSH, SalleeF, LopezFA, LyneA, TremblayG: Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs, 24:755–768, 2010.
21.
CoughlinCG, CohenSC, MulqueenJM, Ferracioli-OdaE, StuckelmanZD, BlochMH: Meta-analysis: Reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 25:611–617, 2015.
22.
DobsonET, StrawnJR: Placebo response in pediatric anxiety disorders: Implications for clinical trials design and interpretation. J Child Adolesc Psychopharmacol, 26:686–693, 2016.
23.
DrakeC, NickelC, BurduvaliE, RothT, JeffersonC, PietroB: The Pediatric Daytime Sleepiness Scale (PDSS): Sleep habits and school outcomes in middle-school children. Sleep, 26:455–458, 2003.
24.
FiksA, MayneSL, SongL, SteffesJ, LiuW, McCarnB, MargolisB, GrimesA, GotliebE, LocalioR, RossME, GrundmeierRW, WassermanR, LeslieLK: Changing patterns of alpha agonist medication use in children and adolescents 2009–2011. J Child and Adol Psychopharm, 25:362–367, 2015.
KaplowJB, CurranPJ, AngoldA, CostelloEJ: The prospective relation between dimensions of anxiety and the initiation of adolescent alcohol use. J Clin Child Psychol, 30:316–326, 2001.
NewcornJH, SchulzK, HarrisonM, DeBellisMD, UdarbeJK, HalperinJM: Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am, 45:1099–1022, 1998.
32.
NewcornJH, SteinMA, ChildressAC, YouchaS, WhiteC, EnrightG, RubinJ: Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: Morning or evening administration. J Am Acad Child Adolesc Psychiatry, 52:921–930, 2013.
33.
OwensJA, SpiritoA, McGuinnM: The Children's Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep, 23:1043–1051, 2000.
34.
PineDS, CohenP, GurleyD, BrookJ, MaY: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry, 55:56–64, 1998.
35.
PosnerK, BrownGK, StanleyB, BrentDA, YershovaKV, OquendoMA, CurrierGW, MelvinGA, GreenhillL, ShenS, MannJJ: The Columbia–suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry, 168:1266–1277, 2011.
36.
RutherfordBR, WallMM, BrownPJ, ChooTH, WagerTD, PetersonBS, ChungS, KirschI, RooseSP: Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatry, 2016. [Epub ahead of print]. DOI: 10.1176/appi.ajp.2016.16020225.
37.
RynnM, PuliaficoA, HeleniakC, RikhiP, GhalibK, VidairH: Advances in pharmacotherapy for pediatric anxiety disorders. Depress Anxiety, 28:76–87, 2011.
38.
RynnMA, RiddleMA, YeungPP, KunzNR: Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials. Am J Psychiatry, 164:290–300, 2007.
39.
RynnMA, SiquelandL, RickelsK: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry, 158:2008–2014, 2001.
40.
SalleeFR, McGoughJ, WigalT, DonahueJ, LyneA, BiedermanJ: Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48:155–165, 2009.
41.
SeidelL, WalkupJT: Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol, 16:171–179, 2006.
42.
SoeterM, KindtM: An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry, 78:880–886, 2015.
43.
StrawnJR, DobsonET, MillsJA, CornwallGJ, SakolskyDJ, BirmaherB, ComptonSN, PiacentiniJ, McCrackenJT, GinsburgGS, KendallPC, WalkupJT, AlbanoAM, RynnMA: Placebo response in pediatric anxiety disorders: Results from the Child/adolescent Anxiety Multimodal Study. J Am Acad Child Adolesc Psychiatry, 55:S230, 2016.
44.
StrawnJR, PrakashA, ZhangQ, PangalloBA, StroudCE, CaiN, FindlingRL: A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry, 54:283–293, 2015a.
45.
StrawnJR, SakolskyDJ, RynnMA: Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc Psychiatr Clin N Am, 21:527–539, 2012a.
46.
StrawnJR, WehryAM, DelBelloMP, RynnMA, StrakowskiS: Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety, 29:328–339, 2012b.
47.
StrawnJR, WelgeJA, WehryAM, KeeshinB, RynnMA: Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta-analysis. Depress Anxiety, 32:149–157, 2015b.
48.
TanakaM, YoshidaM, EmotoH, IshiiH: Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: Basic studies. Eur J Pharmacol, 405:397–406, 2000.
49.
WalkupJT, AlbanoAM, PiacentiniJ, BirmaherB, ComptonSN, SherrillJT, GinsburgGS, RynnMA, McCrackenJ, WaslickB, IyengarS, MarchJS, KendallPC: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med, 359:2753–2766, 2008.
50.
WalkupJT, LabellarteMJ, RiddleMA, PineDS, GreenhillL, KleinR, DaviesM, SweeneyM, AbikoffH, HackS, McCrackenJ, BergmanL, PiacentiniJ, MarchJ, ComptonS, RobinsonJ, O'HaraT, BakerS, VitielloB, RitzL, RoperM: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med, 344:1279–1285, 2001.
51.
WehryAM, Beesdo-BaumK, HennellyMM, ConnollySD, StrawnJR: Assessment and treatment of anxiety disorders in children and adolescents. Curr Psychiatry Rep, 17:52, 2015.
WilensTE, BuksteinO, BramsM, CutlerAJ, ChildressA, RuginoT, LyneA, GrannisK, YouchaS: A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 51:74–85, 2012.
54.
WoodwardLJ, FergussonDM: Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry, 40:1086–1093, 2001.
55.
ZimmermannP, WittchenHU, HoflerM, PfisterH, KesslerRC, LiebR: Primary anxiety disorders and the development of subsequent alcohol use disorders: A 4-year community study of adolescents and young adults. Psychol Med, 33:1211–1222, 2003.
